Language

CAS No. 1420477-60-6 | Acalabrutinib

Name: Acalabrutinib CAS No. 1420477-60-6 MF:C26H23N7O2 MW:465.51 Purity:98% Package: 5g,25g,200g,500g,1kg Worldwide Delivery

Categories：

Other Life Science Chemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 1420477-60-6 | Acalabrutinib

Synonyms:acalabrutinib;

Benzamide,4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-;

ACP196,Acalabrutinib;

4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide;

(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide;

Specification:

ITEMS	SPECIFICATION
CAS	1420477-60-6
MF	C26H23N7O2
MW	465.51
Melting point	>133°C
Density	1.37±0.1 g/cm3
Acidity coefficient	11.47±0.70
Color	sticky yellow
Solubility	Soluble in DMSO (at least 25 mg/ml)
Form	Solid
Storage condition	Refrigerator

Introduction:

Acalabrutinib (ACP-196) is a selective second-generation BTK inhibitor that inhibits the activation of the primary antibody signaling pathway on the surface of B cells. It has excellent target specificity and is 323-, 94-, 19-, 9-fold more selective for BTK than other TEC kinase family members such as ITK, TXK, BMK and TEC. No activity against EGFR.

use:

ACP-196 is an experimental anti-cancer drug that is a selective Bruton tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B-cell receptor (BCR), so any inherited BTK mutation results in B-cell immune deficiency. Therefore, BTK inhibitors targeting B cell signaling have shown great promise in treating chronic lymphocytic leukemia (CLL). Acalabrutinib is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B-cell receptor (BCR), so any mutation in the BTK gene results in B-cell immune deficiency. Therefore, BTK inhibitors targeting B cell signaling show great potential in the treatment of chronic lymphocytic leukemia (CLL).

Mechanism:

Acalabrutinib is a second-generation small molecule Bruton's tyrosine kinase inhibitor. Acalatinib and its metabolite ACP-5862 form covalent binding to the cysteine residue at position 481 of the active site of BTK, inhibiting the activity of the BTK enzyme; BTK acts as a B cell antigen receptor and a cytokine receptor. Channel signaling molecules. In B cells, the activation of BTK signaling is a channel signal necessary to promote B cell proliferation, transport, chemotaxis, and adhesion. Acalabrutinib and its metabolites selectively block the BTK pathway without damaging other molecular pathways important for platelets and immune function, thereby avoiding or reducing the occurrence of adverse reactions related to cancer therapy.

Package and transportation :

Package: 5g,25g,200g,500g,1kg